The next generation biopharmaceuticals

Affibody enters agreement with ACELYRIN for the development and commercialization of izokibep at a total deal value of USD 305 million plus royalties

2021-11-16

Affibody enters agreement with ACELYRIN for the development and commercialization of izokibep at a total deal value of USD 305 million plus royalties

Solna, Sweden, November 16, 2021. Affibody AB today announced a partnership agreement with ACELYRIN, INC., (“ACELYRIN”) to develop and commercialize izokibep, a bispecific molecule targeting interleukin-17A (IL-17), for multiple autoimmune diseases. Under the terms of the agreement, Affibody will receive a USD 25 million upfront payment and is eligible to receive up to USD 280 million in additional regulatory and sales milestones, plus high single-digit to low double-digit royalties on sales.

Under the terms of the transaction, ACELYRIN has obtained worldwide rights to izokibep except development and commercialization already granted to Affibody’s partner Inmagene Biopharmaceuticals Co., Ltd. (“Inmagene”) in selected Asian countries. Additionally, Affibody is retaining commercialization rights in the Nordic countries.

“As the innovators of izokibep, we’re honored to work with ACELYRIN to unlock this molecule’s potential and address promising new indications and solve unmet needs. In addition, we look forward to working with the ACELYRIN team to select additional targets and build new programs, in parallel with the development of izokibep,” said David Bejker, CEO, Affibody AB. “The partnership agreement with ACELYRIN has potential to bring us revenues of more than USD 300 million plus royalties, and complements our established partnership with Inmagene.”

Izokibep is a unique, antibody mimetic, IL-17A inhibitor designed to overcome the limitations of monoclonal antibodies. With extraordinary potency and small molecular size, izokibep can reach high drug exposure levels through a single subcutaneous injection that monoclonal antibodies require IV administration to achieve. In addition, the molecule’s small size—about a tenth the size of a monoclonal antibody—also enables its potential to reach targeted tissues that may otherwise be inaccessible to the much larger monoclonal antibodies.

More than 300 patients have been dosed with izokibep to date, many for up to three years. These data confirm the safety profile of izokibep and support the strategy of fully evaluating IL-17A inhibition in pursuit of transformative efficacy across many disease states.

“We are excited about this partnership with Affibody and look forward to rapidly advancing the late-phase development of izokibep. We aim to demonstrate the potential for differentiation of izokibep within the class of IL-17 inhibitors with its well-understood mechanism of action, both by unlocking new indications as well as achieving differentiated efficacy in existing blockbuster indications, where significant unmet needs persist.” said Shao-Lee Lin, M.D., Ph.D., co-founder CEO, ACELYRIN.

Affibody is a clinical stage biopharmaceutical company with a broad product pipeline focused on developing innovative bi- and multi-specific next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod®.

The company operates a focused experimental medicine model and currently has two clinical stage programs. The first, izokibep (ABY-035) is a therapeutic program that target IL-17. The second program, ABY-025, is a diagnostic imaging program that is directed primarily towards metastatic breast cancer.

Affibody AB is a holding of Patricia Industries.

Further information can be found at: www.affibody.com

Affibody in short

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Upcoming reports Financial calendar

  • Interim Report January to March 2020 (May 15, 2020)
  • Interim Report January to June 2020 (August 21, 2020)
  • Interim Report January to September 2020 (November 13, 2020)
  • Year End Report 2020 (February 2021)